Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Faces New Round Of Risperdal Suits With Ghostwriting Claims

Executive Summary

Johnson & Johnson has been hit with another wave of Risperdal (risperidone) product liability suits. While previous suits have claimed the antipsychotic caused diabetes, the current batch alleges that the drug induced gynecomastia, or breast enlargement, in boys and young men

You may also be interested in...



The New Ghostbuster: Elsevier Reviews Articles On Wyeth Drugs

Elsevier's investigation follows reports that Wyeth hired an outside company to write positive articles about its drugs; publisher also responds to Sen. Grassley letter.

Merck Accepts DTC Limits In Deal With States

Firm to pay $58 million to settle claims its consumer ads deceived the public on Vioxx safety.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Topics

UsernamePublicRestriction

Register

ID1132082

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel